HealthMore in Health→
Pharma Industry Reshapes Licensing Deals to Blunt MFN Drug Pricing
Key Takeaways
- Pharma companies are restructuring international licensing agreements to reduce price transparency that MFN calculations would use
- Lawyers confirm the strategies are legal adaptations to evolving MFN rules, not evasion schemes
- Biologics face the biggest MFN exposure due to the largest US-to-global price gaps in that drug category
DE
DT Editorial Team··3 min read·via endpoints.news
